Article
Medical Laboratory Technology
Christina H. Wei, Lino Garcia, Joyce Murata-Collins, Daniel Schmolze, Sophia Apple
Summary: The new 2018 ASCO/CAP guidelines have led to an average 9% reclassification rate for HER2 status, resulting in a net gain in overall HER2 negative designation. Inconsistent discordance between Group 1/5 and FISH results has been observed, emphasizing the importance of recognizing potential issues with tumor heterogeneity and discordance between IHC and FISH in clinical assessment of HER2 test results.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2021)
Article
Oncology
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal Lindeman, Kathleen Moore, Shridar Ganesan, Christine M. Lovly, Jane Perlmutter, Stacy W. Gray, Jimmy Hwang, Christopher Lieu, Fabrice Andre, Nilofer Azad, Mitesh Borad, Laura Tafe, Hans Messersmith, Mark Robson, Funda Meric-Bernstam
Summary: ASCO's provisional clinical opinion provides guidance on the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. Genomic sequencing should be performed in a certified laboratory for patients with specific genomic alterations that have regulatory approval as biomarkers. Multigene panel-based assays can be used to identify additional treatment targets. Site-agnostic approvals for cancers with high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase (NTRK) fusions justify genomic testing for all solid tumors. The functional impact of targeted alterations and the expected efficacy of genomic biomarker-linked options should be considered for treatment planning.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Dermatology
Sun Hye Shin, Young Gue Koh, Woo Geon Lee, Joon Seok, Kui Young Park
Summary: Epidermal growth factor (EGF) is essential for wound healing and tissue homeostasis. Recombinant human EGF (rhEGF) has been proven to promote skin wound healing and has potential clinical applications in dermatological conditions beyond wound healing. However, there is a scarcity of studies on its use in these conditions. In this article, we searched PubMed/Medline and Google Scholar databases to summarize the effects of rhEGF in various skin problems.
INTERNATIONAL WOUND JOURNAL
(2023)
Article
Oncology
Janakiraman Subramanian, Natasha B. Leighl, Yoon-La Choi, Teh-Ying Chou, Jeffrey Gregg, Rina Hui, Antonio Marchetti, Mark Silvey, Rebecca Makin, Liane Gillespie-Akar, Aliki Taylor, Doreen A. Kahangire, Tom Bailey, Maiyan Chau, Neal Navani
Summary: This real-world study explored treatment patterns and time to receive EGFRm test results in patients with advanced EGFRm NSCLC. Over one-fifth of patients wait >14 days for their EGFRm test results, affecting their likelihood of receiving first-line EGFR-TKI treatment.
Review
Medical Laboratory Technology
Saeam Shin, Hye In Woo, Jong-Won Kim, Yoonjung Kim, Kyung-A Lee
Summary: Standardization of pre-analytical procedures is essential for obtaining clinically reliable results in cfDNA testing. This article provides evidence-based clinical practice guidelines for the pre-analytical phase procedures of plasma EGFR variant testing. By standardizing pre-analytical procedures, the analytical performance of cfDNA testing can be improved.
ANNALS OF LABORATORY MEDICINE
(2022)
Article
Immunology
How-Wen Ko, Shian-Sen Shie, Chih-Wei Wang, Chi-Tsun Chiu, Chih-Liang Wang, Tsung-Ying Yang, Shou-Chu Chou, Chien-Ying Liu, Chih-Hsi Scott Kuo, Yu-Ching Lin, Li-Fu Li, Cheng-Ta Yang, Chin-Chou Wang
Summary: This study identifies a comprehensive spectrum of uncommon EGFR mutations and demonstrates a positive relationship between smoking status and the frequency of uncommon EGFR mutations, particularly complex uncommon EGFR mutations. The results suggest that smoking contributes to the development of complex EGFR mutations.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Lihui Liu, Chao Wang, Sini Li, Hua Bai, Jie Wang
Summary: The tumor immune microenvironment (TIME) in EGFR-mutated NSCLC differs from non-mutated NSCLC, leading to poor response to ICIs. TIME in EGFR-mutated NSCLC changes during EGFR-TKI treatment. In EGFR-TKI-resistant tumors, there is an increase in immunosuppressive cells, decrease in immune-activated cells, and secretion of negative immune regulatory factors, resulting in immune escape and eventual resistance to EGFR-TKIs.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Summary: The study revealed that MYLK4 promotes the growth and metastasis of osteosarcoma by activating the EGFR signaling pathway. Additionally, the combination of MYLK4 and EGFR inhibitors showed synergistic effects on the growth and metastasis of OS in vitro and in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biology
Yongjian Huang, Jana Ognjenovic, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan
Summary: Research has shown that the EGFR receptor can adopt different conformations of the extracellular module when binding to different ligands, with implications for intracellular signaling pathways.
Article
Oncology
Harold Burstein, Angela R. DeMichele, Mark Somerfield, N. Lynn Henry
Summary: ASCO Rapid Recommendations Updates revise selected ASCO guideline recommendations in response to new and practice-changing data. These updates are based on evidence reviews and follow ASCO's Guideline Methodology Manual. The aim is to promptly disseminate updated recommendations to enhance cancer care decisions for healthcare professionals and the public.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Brendan Sullivan, Taylor Light, Vinh Vu, Adrian Kapustka, Kalina Hristova, Deborah Leckband
Summary: This study reveals a force-transduction mechanism that connects mechanical perturbations of E-cadherin to the activation of EGFR, a key regulator of cell proliferation. The results demonstrate that E-cadherin and EGFR form complexes at the plasma membrane, which are disrupted by the application of force or the presence of EGF. The findings provide insights into the initial steps of E-cadherin-mediated force transduction and the activation of growth regulatory signaling cascades.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
Summary: This article is an update on the recommendations for HER2 testing in breast cancer, affirming the 2018 ASCO-CAP recommendations. The article emphasizes a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified, and provides best practice recommendations to distinguish IHC 0 and 1+.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Anita Brouns, Safiye Dursun, Gerben Bootsma, Anne-Marie C. Dingemans, Lizza Hendriks
Summary: Around 30-60% of lung cancer patients develop bone metastases, with those carrying an EGFR mutation being more prone to it. However, there is still a lack of research on bone metastases in clinical trials.
Review
Pharmacology & Pharmacy
Jazlyn P. Borges, Katrina Mekhail, Gregory D. Fairn, Costin N. Antonescu, Benjamin E. Steinberg
Summary: Chronic pain is a major public health issue that is often resistant to conventional analgesics. Recent studies have implicated the epidermal growth factor receptor (EGFR) signaling pathway in chronic pain, suggesting potential therapeutic targets for this devastating condition.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Camille Leonce, Clemence Guerriau, Lara Chalabreysse, Michael Duruisseaux, Sebastien Couraud, Marie Brevet, Pierre-Paul Bringuier, Delphine Aude Poncet
Summary: Targeting EGFR alterations, particularly the L858R (Exon 21) mutation and Exon 19 deletion (del19), has significantly improved the survival of lung cancer patients. The study compared two rapid strategies for EGFR testing and found that ddPCR has higher sensitivity in detecting unique del19, while Idylla is an alternative in other situations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
